PE20081200A1 - Sal de potasio cristalina de analogos de lipoxina a4 - Google Patents

Sal de potasio cristalina de analogos de lipoxina a4

Info

Publication number
PE20081200A1
PE20081200A1 PE2007001704A PE2007001704A PE20081200A1 PE 20081200 A1 PE20081200 A1 PE 20081200A1 PE 2007001704 A PE2007001704 A PE 2007001704A PE 2007001704 A PE2007001704 A PE 2007001704A PE 20081200 A1 PE20081200 A1 PE 20081200A1
Authority
PE
Peru
Prior art keywords
potassium salt
refers
crystalline potassium
salt
lipoxin
Prior art date
Application number
PE2007001704A
Other languages
English (en)
Spanish (es)
Inventor
Tilo Haag
Danja Grossbach
Gabriele Winter
Michael Sander
Wolfgang Beckmann
Klaus Bartel
Christian Dinter
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39076610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20081200A1 publication Critical patent/PE20081200A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
PE2007001704A 2006-12-04 2007-12-03 Sal de potasio cristalina de analogos de lipoxina a4 PE20081200A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87283006P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
PE20081200A1 true PE20081200A1 (es) 2008-11-06

Family

ID=39076610

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001704A PE20081200A1 (es) 2006-12-04 2007-12-03 Sal de potasio cristalina de analogos de lipoxina a4
PE2012000006A PE20120395A1 (es) 2006-12-04 2007-12-03 Sal de potasio cristalina de analogos de lipoxina a4

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000006A PE20120395A1 (es) 2006-12-04 2007-12-03 Sal de potasio cristalina de analogos de lipoxina a4

Country Status (28)

Country Link
US (2) US7906678B2 (cg-RX-API-DMAC7.html)
EP (2) EP3489214A1 (cg-RX-API-DMAC7.html)
JP (1) JP5410984B2 (cg-RX-API-DMAC7.html)
KR (3) KR20140135847A (cg-RX-API-DMAC7.html)
CN (1) CN101553456B (cg-RX-API-DMAC7.html)
AR (1) AR064116A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007327765B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719679A2 (cg-RX-API-DMAC7.html)
CA (1) CA2670791C (cg-RX-API-DMAC7.html)
CL (1) CL2007003468A1 (cg-RX-API-DMAC7.html)
CO (1) CO6190608A2 (cg-RX-API-DMAC7.html)
CR (1) CR10837A (cg-RX-API-DMAC7.html)
DO (1) DOP2009000130A (cg-RX-API-DMAC7.html)
EA (1) EA018615B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099380A (cg-RX-API-DMAC7.html)
IL (1) IL198434A (cg-RX-API-DMAC7.html)
MA (1) MA31079B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009005911A (cg-RX-API-DMAC7.html)
MY (1) MY147951A (cg-RX-API-DMAC7.html)
NO (1) NO20092528L (cg-RX-API-DMAC7.html)
NZ (1) NZ577338A (cg-RX-API-DMAC7.html)
PE (2) PE20081200A1 (cg-RX-API-DMAC7.html)
SV (1) SV2009003286A (cg-RX-API-DMAC7.html)
TN (1) TN2009000167A1 (cg-RX-API-DMAC7.html)
TW (1) TWI415833B (cg-RX-API-DMAC7.html)
UY (1) UY30755A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008068041A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200904689B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081200A1 (es) * 2006-12-04 2008-11-06 Bayer Schering Pharma Ag Sal de potasio cristalina de analogos de lipoxina a4
US20090036530A1 (en) * 2006-12-04 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Crystalline acid of lipoxin A4 analogs and method of making
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2470189A4 (en) * 2009-08-27 2013-01-23 Merck Sharp & Dohme METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
CA3149053A1 (en) * 2013-02-21 2014-08-28 Forsyth Dental Infirmary For Children Methods for increasing oral osteogenesis using lipoxin a4 (lxa4) and its analogs
CN114377138A (zh) * 2015-03-18 2022-04-22 福塞斯儿童牙科医院 使用脂氧素、消退素及其类似物稳定动脉粥状硬化斑块的方法
ES2827796T3 (es) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
WO2018144316A1 (en) 2017-01-31 2018-08-09 The Brigham And Women's Hospital, Inc. Alx receptor ligands define a biochemical endotype for inflammation-based diseases
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
DE69435125D1 (de) 1993-06-15 2008-10-02 Brigham & Womens Hospital Lipoxinverbindungen mit verlängerter halbwertszeit
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
WO1995001179A1 (en) 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6236978B1 (en) * 1997-11-14 2001-05-22 New York University System and method for dynamic profiling of users in one-to-one applications
US6006466A (en) * 1998-08-20 1999-12-28 Washecka; John Concealed linear payout holder for fishing leader
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
CA2367909C (en) 1999-03-18 2008-02-12 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response
US6353026B1 (en) 1999-03-18 2002-03-05 Brigham And Women's Hospital Regulation of phospholipase D activity
JP2002539181A (ja) 1999-03-18 2002-11-19 ブリガム・アンド・ウイメンズ・ホスピタル リポキシン化合物およびこれらの使用
ATE258791T1 (de) 1999-11-09 2004-02-15 Alcon Inc Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
US7700650B2 (en) 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
AU2002347539A1 (en) 2001-12-13 2003-06-23 Ranbaxy Laboratories Limited Crystalline cefdinir potassium dihydrate
AU2003209562A1 (en) 2002-03-15 2003-09-29 Dr. Reddy's Laboratories Limited Novel crystalline form of 5-(4-((3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy)benzyl)thiazolidine-2,4-dione potassium salt
ATE487478T1 (de) 2003-01-30 2010-11-15 Lek Pharmaceuticals Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
WO2006035291A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Crystalline forms of cefdinir potassium
US7223718B2 (en) * 2005-03-07 2007-05-29 Falcon Lab Llc Enhanced glyphosate herbicidal concentrates
US20070191331A1 (en) 2005-10-31 2007-08-16 Kansal Vinod K Crystalline forms of cefdinir potassium salt
PE20081200A1 (es) * 2006-12-04 2008-11-06 Bayer Schering Pharma Ag Sal de potasio cristalina de analogos de lipoxina a4

Also Published As

Publication number Publication date
DOP2009000130A (es) 2009-08-15
JP5410984B2 (ja) 2014-02-05
PE20120395A1 (es) 2012-05-23
EA200900732A1 (ru) 2009-12-30
US8049035B2 (en) 2011-11-01
EP2089350B1 (en) 2018-08-22
KR20160054030A (ko) 2016-05-13
NZ577338A (en) 2011-02-25
CR10837A (es) 2009-07-23
WO2008068041A1 (en) 2008-06-12
US20080182897A1 (en) 2008-07-31
CA2670791C (en) 2017-01-03
AU2007327765A1 (en) 2008-06-12
MX2009005911A (es) 2009-09-07
NO20092528L (no) 2009-08-26
ECSP099380A (es) 2009-11-30
EP3489214A1 (en) 2019-05-29
CA2670791A1 (en) 2008-06-12
UY30755A1 (es) 2008-07-31
US7906678B2 (en) 2011-03-15
MA31079B1 (fr) 2010-01-04
AR064116A1 (es) 2009-03-11
TN2009000167A1 (en) 2010-10-18
CO6190608A2 (es) 2010-08-19
MY147951A (en) 2013-02-15
ZA200904689B (en) 2011-10-26
EA018615B1 (ru) 2013-09-30
CL2007003468A1 (es) 2008-07-04
TW200838847A (en) 2008-10-01
JP2010511649A (ja) 2010-04-15
KR20090101169A (ko) 2009-09-24
US20110124910A1 (en) 2011-05-26
EP2089350A1 (en) 2009-08-19
IL198434A0 (en) 2010-02-17
IL198434A (en) 2012-09-24
TWI415833B (zh) 2013-11-21
BRPI0719679A2 (pt) 2014-01-14
CN101553456B (zh) 2013-08-28
SV2009003286A (es) 2009-10-02
HK1135961A1 (en) 2010-06-18
CN101553456A (zh) 2009-10-07
AU2007327765B2 (en) 2012-04-12
KR20140135847A (ko) 2014-11-26

Similar Documents

Publication Publication Date Title
PE20081200A1 (es) Sal de potasio cristalina de analogos de lipoxina a4
PE20071176A1 (es) Derivados diamina como inhibidores de leucotrieno a4 hidrolasa
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
MX2013004242A (es) Sulfonamidas nematocidas.
PE20142042A1 (es) Forma termodinamicamente estable de una sal tosilato de sorafenib
PE20081532A1 (es) Compuestos novedosos
MX2012006562A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-( 4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas.
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
CY1109307T1 (el) Χρηση αδαπαλενιου για τη θεραπεια δερματολογικων διαταραχων
BRPI0517568B8 (pt) Transistor de efeito de campo
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
EA200602038A1 (ru) Азинилимидазоазины и азинилкарбоксамиды
NZ599797A (en) Isoxazoline compositions and their use as antiparasitics
BR0306559A (pt) Forma de aplicação oral para etilésteres de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamin o]-metil}-1-metil-1h-ben-zimidazol-5-carbonil)-piridin- 2-il-amino]-propiÈnico e seus sais
ATE442364T1 (de) Kristalline form von linezolid
PE20081135A1 (es) Derivados que contienen sulfamoilo y sus usos
AR047085A1 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad
PE20080364A1 (es) Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa
ATE520406T1 (de) Kristalline form des ibandronat-natriums
ATE403375T1 (de) Pestizide zusammensetzung enthaltend einen laktat ester als kristallwachstumshemmer
CY1109740T1 (el) Νεα μεθοδος συνθεσης παραγωγων της 1,3,4,5 -τετραϋδρο-2η- 3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης της σε ενα φαρμακευτικως αποδεκτο οξυ
PE20080175A1 (es) Sales de malato, y polimorfos de acido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico
CL2013003574A1 (es) Composicion para el cuidado oral que comprende a) 0,1-4% en peso de uno o mas catequinas, b) 0,1 a 10% en peso de una sal de zinc seleccionada entre zncl2, zn(no3)2, y acetato de zinc o sus mezclas; c) una base oralmente aceptable que comprende carbonato de calcio; uso de la composicion para un beneficio antiinflamatorio.
AR053099A1 (es) Una composicion de detergente

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed